MagForce AG Announces Positive Results Of 2014 Annual General Meeting
• The Annual General Meeting approves all agenda items with a clear majority
• Supervisory Board change: Dr. Wiebke Rösler elected as new Supervisory Board member, replacing Bernd Förtsch
Berlin, Germany, August 19, 2014 - MagForce AG (Frankfurt, Entry Standard, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, held its Annual General Meeting in Berlin today. The Annual General Meeting approved all resolution items with a clear majority.
Longtime Supervisory Board member Bernd Förtsch will leave the Supervisory Board as of the end of today. The Annual General Meeting elected Dr. Wiebke Rösler as a new member to replace him. Dr. Rösler studied medicine at the Medizinische Hochschule Hannover [Hanover Medical School], earning her Ph.D. in the area of native-radiological diagnostics. She has many years of experience as an internist specializing in hematology and oncology. After Dr. Jan zur Hausen resigned from his position on September 13, 2013, the Charlottenburg Local Court resolved to appoint Stephan Jakober as a member of the Supervisory Board from October 1, 2013. As he had been court appointed, the Annual General Meeting formally confirmed Mr. Stephan Jakober as a Supervisory Board member. The CEO and Chairman of the Management Board, Dr. Ben J. Lipps, provided a status update on current operational developments, an overview of the 2013 fiscal year, and an outlook for the current year. In ad dition, he explained his strategic five-year plan in detail.
The Management Board and Supervisory Board were pleased about the successful election results, and thanked Mr. Förtsch and Dr. zur Hausen for their engagement. Dr. Ben J. Lipps stated, 'I would like to thank Mr. Förtsch for his many years of commitment to MagForce. His extraordinary dedication rightfully qualifies him as one of the key supporters behind our innovative therapy. I would also like to express my gratitude to Dr. zur Hausen for his contribution during a difficult transition period.'
The Management Board presentation is available on the Company's website at www.magforce.de/en/presse-investoren/hauptversammlung .
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit: www.magforce.com .
Please learn more: video (You Tube)
Help employers find you! Check out all the jobs and post your resume.